the tarsal plate, as in our case. [1] Sudden onset of lesions at night can be explained by the nocturnal exacerbation of cough and increased fragility of vessels because of old age of the patient; left lateral positioning of the patient while sleeping can explain ecchymosis limited to the left eye and extending to the temples and cheek as well as the medial canthus of the right eye. The facial veins receive tributaries from the side of the nose and from the inferior palpebral, superior, and inferior labial veins, the buccinators, parotid and masseteric veins, as well as other tributaries which join it below the mandible. The facial veins communicate to the cavernous veins via the superior and inferior ophthalmic veins which drain either separately or by a common trunk to the cavernous sinus. [1] Coughing leads to an increase in cerebral venous pressure which is transmitted via cavernous sinus to orbital and facial venous system resulting in bruising. [4] Al-Sardar reported perioral involvement caused by vomiting which can be explained by the drainage of superior and inferior labial veins into facial venous system, which further communicates to cavernous system by ophthalmic veins. [1] Hence, the transmission of increased cerebral venous pressure during Valsalva maneuver to facial venous system may also lead to perioral ecchymosis but our patient had no other site involvement on face due to ecchymosis except periorbital area.
Facial ecchymosis has also been reported with other benign conditions associated with valsalva maneuver such as coughing, vomiting, sneezing, and power lifting. [1, 2, 5, 6] Hence, we would like to stress that these benign conditions should be considered in the differential diagnosis of periorbital purpura on excluding bleeding disorders, trauma, and intracranial pathologies after appropriate investigations.
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Pseudo Acne Fulminans: An Under Recognized Entity
Sir, A 17-year-old young male presented to us with a recent (1 week) flare up of his acne lesions on face. The patient was receiving oral isotretinoin 20 mg daily for around 3 weeks prescribed by another dermatologist. On examination, he had multiple painful, tender crusts and scabs on face; along with few scattered pustules.
On removing the crusts, pus-filled pockets were seen. On stretching the skin, multiple closed comedones were also found [ Figure 1 ]. His systemic examination was unremarkable. Routine hematological and biochemical investigations were normal.A clinical diagnosis of pseudo acne fulminans (AF) was made. Oral isotretinoin was withdrawn and the patient was started on oral prednisolone with a dose of 30 mg daily under the cover of antibiotics. Improvement in cutaneous lesions was observed as early as within 2-3 days of treatment [ Figure 2] . Oral prednisolone was then slowly tapered over the next 3-4 weeks.
We have been seeing similar cases of pseudo AF on a fairly regular basis in our outpatient department. In some of these cases, patients erupted with very tender nodules and fluctuant lesions following oral isotretinoin, without any systemic features [ Figure 3 ].
The idea of sharing this case and cases similar to this is to highlight pseudo AF, a condition which we believe is more common than what has been described in literature.
AF is a rare and serious condition characterized by the sudden onset of nodular and ulcerative acne lesions associated with systemic symptoms. [1, 2] In contrast, pseudo AF or AF "sine fulminans" is observed in a subset of acne patients who develop sudden worsening of acne, often during treatment with oral isotretinoin, but without strong presence of systemic involvement. [2, 3] Thomson and Cunliffe [3] reported 14 cases of acne with severity comparable to AF but without systemic involvement. A common characteristic to virtually all patients was the presence of macrocomedones and use of oral isotretinoin before the onset of the clinical picture. This is similar to what we have described in the above case. The most accepted mechanism for the onset of pseudo AF is a hypersensitivity reaction to bacterial antigens of Propionibacterium acnes released during treatment with oral isotretinoin. [4] However, in our view, there might be some other factors also. Probably in some acne patients follicular wall is thin and it gets easily ruptured on exposure to isotretinoin. Once the substances of follicular canals are released in dermis, they recruit immune cells and it leads to an aggravated immune response. In addition, a majority of acne patients who come for treatment to us are not treatment-naive. They often come after having applied topical steroids for variable duration. Use of topical steroids may further lead to thinning of their follicular wall. To avoid development of this troublesome condition in patients with macrocomedones, previous studies have suggested early introduction of prednisone with a dose of 0.5 or 1.0 mg/kg/day for 4-6 weeks slowly decreasing later on. [2, 3] Oral isotretinoin should be initiated only when the inflammation settles and that too at a very low dose of 0.25-0.5 mg/kg/day; dose of isotretinoin can then be increased and corticosteroid gradually tapered off. [5] We believe that the incidence of this entity is quite high at least in Indian context. Every dermatologist who deals with acne should be well versed with this entity.
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Secukinumab in Generalized Pustular Psoriasis
Sir, Generalized pustular psoriasis (GPP) is a potentially life threatening condition. Acute GPP, also called the von Zumbusch type, often starts abruptly, is associated with painful skin lesions, fever, and chills, and carries a significant morbidity in the absence of appropriate treatment. The disease can also run a chronic course. [1] The first and second line treatments for GPP include acitretin, cyclosporine, methotrexate, and infliximab. Second line includes adalimumab, etanercept, PUVA, topical steroids, topical calcipotriene, and topical tacrolimus. [1] Secukinumab is a new biologic approved in June 2015 by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis. It is a human monoclonal antibody that inhibits only IL-17A, leaving the IL-17F component for valuable immunity.
There are a few case reports showing the efficacy of secukinumab in pustular psoriasis. [2] [3] [4] [5] We report a young lactating mother with GPP who responded dramatically after the first injection of secukinumab.
A 25-year-old married female was admitted in the emergency department with fever and erythematous scaly plaques studded with pustules for approximately 2 weeks. She had been on methotrexate 10 mg/week 2 years ago. She had plaque psoriasis for over 3 years and developed pustular psoriasis for the last 2 weeks.
She was lactating and her baby was 4 months old. Her PASI (psoriasis area severity index) was 30.2 on admission [ Figures 1 and 2] . Her investigations revealed leucocytosis, raised ESR, CRP, and elevated liver enzymes. Although her blood culture did not show any growth, she was started on IV antibiotics (cefoperazone sulbactam). Screening for tuberculosis and viral markers were negative. As she was of child bearing age, and liver enzymes were elevated, acitretin and methotrexate were not considered. We started her on cyclosporine 150 mg/day as she was lactating. After 1 week her fever subsided but there was no improvement in her skin lesions. Therefore, she was started on inj. secukinumab weekly 300 mg subcutaneous (week 0, 1, 2, 3, 4) and thereafter monthly for 3 months. The drug was continued for another 2 months at 150 mg/month after which it was stopped. Her pustules resolved after the first injection [ Figures 3 and 4 ]. After almost 2 years of stopping the injections, the patient is still in remission and her child who is 2 years old now is normal.
Diagnostic criteria for GPP include: (1) multiple sterile pustules on erythematous skin; (2) systemic symptoms such as fever and malaise; (3) the presence of histopathologically confirmed spongiform pustules; and (4) one or more of the following laboratory test alterations: leukocytosis with left shift, elevated erythrocyte sedimentation rate, elevated CRP, high antistreptolysin O antibody levels, elevation of IgG or IgA, hypoproteinemia, and hypocalcemia. [6] 
